Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm (two cohorts), single-center, phase II pilot-study to
provide preliminary evidence whether hepatitis B immunoglobulins (HBIG) are efficacious and
can be safely used in patients with chronic Hepatitis B Virus (HBV) infection.
A total of 20 patients (male or female adults aged ≥ 18 years) will be enrolled in the study
and receive hepatitis B immunoglobulins Hepatect®CP and Zutectra®.